Abstract | OBJECTIVE: METHODS: We conducted a retrospective review of all patients seen at our institution from February 2004 to October 2008 who received bevacizumab for ovarian sex cord-stromal tumors. We performed immunohistochemical staining for vascular endothelial growth factor ( VEGF) and CD31 when tissue was available; microvessel density was measured based on CD31 staining. Clinical data were abstracted from a chart review. RESULTS: We identified 8 patients who were treated with bevacizumab; 7 had adult granulosa cell tumors and one had a juvenile granulosa cell tumor. All patients had recurrent disease and had been previously treated with cytotoxic chemotherapy (median 3.5 regimens; range, 1-6). One patient had a complete clinical response to bevacizumab therapy, 2 patients had a partial response, 2 patients had stable disease, and 3 patients' disease progressed, yielding a response rate of 38% and a clinical benefit rate of 63%. The median progression-free survival was 7.2 months and overall survival was not reached at a median follow-up of 23.6 months after initiating bevacizumab. VEGF overexpression and microvessel density were associated with poor outcome but sample size was too small to calculate statistical significance. CONCLUSIONS:
|
Authors | Xia Tao, Anil K Sood, Michael T Deavers, Kathleen M Schmeler, Alpa M Nick, Robert L Coleman, Ljiljana Milojevic, David M Gershenson, Jubilee Brown |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 114
Issue 3
Pg. 431-6
(Sep 2009)
ISSN: 1095-6859 [Electronic] United States |
PMID | 19524286
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Platelet Endothelial Cell Adhesion Molecule-1
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Female
- Granulosa Cell Tumor
(blood supply, drug therapy)
- Humans
- Immunohistochemistry
- Middle Aged
- Neovascularization, Pathologic
(drug therapy, metabolism)
- Ovarian Neoplasms
(blood supply, drug therapy, metabolism)
- Platelet Endothelial Cell Adhesion Molecule-1
(metabolism)
- Retrospective Studies
- Vascular Endothelial Growth Factor A
(metabolism)
- Young Adult
|